Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.40 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3540797 | 1.00 | MAPT (0.50) | MAPTPDK1PDK2PDK3PDK4 | |
| SCHEMBL3535329 | 1.00 | MAPT (0.50) | MAPTPDK1PDK2PDK3PDK4 | |
| SCHEMBL3538785 | 1.00 | MAPT (0.50) | MAPTPDK1PDK2PDK3PDK4 | |
| SCHEMBL3536137 | 1.00 | MAPT (0.50) | MAPTPDK1PDK2PDK3PDK4 | |
| SCHEMBL13985605 | 0.88 | MAPT (0.50) | MAPTPDK1PDK2PDK3PDK4 | |
| SCHEMBL13059798 | 0.88 | MAPT (0.50) | MAPTPDK1PDK2PDK3PDK4 | |
| SCHEMBL13059797 | 0.88 | MAPT (0.50) | MAPTPDK1PDK2PDK3PDK4 | |
| SCHEMBL22034017 | 0.87 | MAPT (0.52) | MAPTPDK1PDK2PDK3PDK4 | |
| SCHEMBL2795738 | 0.87 | MAPT (0.52) | MAPTPDK1PDK2PDK3PDK4 | |
| SCHEMBL15935483 | 0.87 | MAPT (0.52) | MAPTPDK1PDK2PDK3PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1976706-B | FGFR3 inhibition and treatment of multiple myeloma | NOVARTIS VACCINES & DIAGNOSTIC | 2012-01-18 | — | — | CN | disclosed |
| CN-100526312-C | Benzimidazole quinolinones and uses thereof | CHIRON CORP (US) | 2009-08-12 | — | — | CN | disclosed |
| EP-1539754-A4 | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2009-02-25 | — | — | EP | disclosed |
| CN-1976706-A | FGFR3 inhibition and treatment of multiple myeloma | CHIRON CORP (US) | 2007-06-06 | — | — | CN | disclosed |
| EP-1692085-A2 | INHIBITION OF FGFR3 AND TREATMENT OF MULTIPLE MYELOMA | Chiron Corporation (US) | 2006-08-23 | — | — | EP | disclosed |
| CN-1692112-A | Benzimidazole quinolinones and uses thereof | CHIRON CORP (US) | 2005-11-02 | — | — | CN | disclosed |
| EP-1539754-A2 | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF | Chiron Corporation (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2005047244-A2 | INHIBITION OF FGFR3 AND TREATMENT OF MULTIPLE MYELOMA | CHIRON CORPORATION (US) | 2005-05-26 | — | — | WO | disclosed |
| EP-1401831-A1 | INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2004-03-31 | — | — | EP | disclosed |
| WO-2004018419-A2 | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF | CHIRON CORPORATION (US) | 2004-03-04 | — | — | WO | disclosed |
| WO-2003004488-A1 | INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2003-01-16 | — | — | WO | disclosed |